Jasper Therapeutics

Update in progress

JSPR (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for diseases driven by mast cells. Its lead candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor signaling through the CD117 receptor on mast and stem cells. The company aims to treat chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Founded in 2018, it is based in Redwood City, California.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive